{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:25:06Z","timestamp":1792506306854,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000329","name":"Novo Nordisk UK Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000836","name":"University of Liverpool","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.eclinm.2024.102777","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T07:43:35Z","timestamp":1723707815000},"page":"102777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study"],"prefix":"10.1016","volume":"75","author":[{"given":"Matthew","family":"Anson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex E.","family":"Henney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Broadwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizheng S.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema H.","family":"Ibarburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102777_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A\u00a02022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.eclinm.2024.102777_bib2","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/nu15112435","article-title":"Nutritional approaches in children with overweight or obesity and hepatic steatosis","volume":"15","author":"Spiezia","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.eclinm.2024.102777_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib4","series-title":"National diabetes statistics report","year":"2024"},{"key":"10.1016\/j.eclinm.2024.102777_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2024.102777_bib6","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102777_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102777_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.eclinm.2024.102777_bib9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2024.102777_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.eclinm.2024.102777_bib11","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc20-3023","article-title":"Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care","volume":"44","author":"Aminian","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2024.102777_bib12","series-title":"EMA statement on ongoing review of GLP-1 receptor agonists","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102777_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2024.102777_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.eclinm.2024.102777_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.102777_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102777_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102777_bib18","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/dom.15148","article-title":"Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison","volume":"25","author":"le Roux","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib19","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc23-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2024.102777_bib20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib21","article-title":"Population level impact of the NHS diabetes prevention programme on incidence of type 2 diabetes in England: an observational study","volume":"19","author":"McManus","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.eclinm.2024.102777_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15028","article-title":"Effectiveness of digital and remote provision of the healthier you: NHS diabetes prevention programme during the COVID-19 pandemic","volume":"40","author":"Barron","year":"2023","journal-title":"Diabet Med"},{"key":"10.1016\/j.eclinm.2024.102777_bib23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib24","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102777_bib25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102777_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121993","article-title":"Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials","volume":"10","author":"Kritchevsky","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2024.102777_bib27","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/j.numecd.2021.05.010","article-title":"Improvement of glycemic control in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Monami","year":"2021","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.eclinm.2024.102777_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"J\u00a0Lipid Atheroscler"},{"key":"10.1016\/j.eclinm.2024.102777_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2024.102777_bib30","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102777_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","article-title":"Evidence that tirzepatide protects against diabetes-related cardiac damages","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eclinm.2024.102777_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.15332","article-title":"5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine","volume":"26","author":"Niu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.15332","article-title":"5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine","volume":"26","author":"Niu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib34","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2024.102777_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","article-title":"Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study","volume":"15","author":"Rizzo","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eclinm.2024.102777_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/STROKEAHA.119.026587","article-title":"Carotid intima-media thickness and the risk of first stroke in patients with hypertension","volume":"51","author":"Sun","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.eclinm.2024.102777_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1474-4422(23)00029-7","article-title":"Treatment-induced neuropathy of diabetes: an underdiagnosed entity","volume":"22","author":"Quiroz-Aldave","year":"2023","journal-title":"Lancet Neurol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T23:34:25Z","timestamp":1728516865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024003560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"alternative-id":["S2589537024003560"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102777","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102777"}}